ELINOR-BATTERIES
29.8.2024 09:01:32 CEST | Business Wire | Press release
The man who led the development of the first giga-factory for the world´s leading EV supplier, partners with Elinor Batteries. The partnership with Morlus Technology accelerates the development of Elinor’s battery manufacturing base in Orkland, Norway.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828783500/en/
Mr. Xi Shen (front left), CEO of Morlus Technology, and Arne Fredrik Lånke (front right), CEO of Elinor, sign the partnership agreement between the two companies. Behind, from left: Dr. Xi Jiang, G.M. of Cell Development of Morlus, Dr. Rong Hao, Director of Technology Research of Morlus, Huaping Liu, V.P. and Chief Engineer of Morlus, Guanglin Wu, V.P. and CFO of Morlus, Truls Johansen, CSO of Elinor Batteries, Sofi Hildonen, EVP of Business Development, Elinor Batteries, Dr. Fengliu Lou, VP of Technology, Elinor Batteries. Photo: Elinor Batteries
Elinor Batteries in Central Norway enters a collaboration with Chinese battery company Morlus Technology. The partnership grants Elinor access to cutting-edge battery technology and world-leading expertise in factory construction and entails that Elinor will have batteries for commercial sale in the European market by the spring of 2025.
“We are honored that world-leading battery technologists have chosen to collaborate with us. This level of expertise does not currently exist in Europe, and it is crucial for our plans to establish a battery value chain in the Nordic region,” says Arne Fredrik Lånke, CEO of Elinor Batteries.
Leading expertise
The founder of Morlus, Shen Xi, has been a driving force of innovation and technology in the battery industry for over 20 years. His merits include leading battery design, factory design and construction for BYD, the world’s largest electric vehicle supplier and a top tier battery company. At BYD, Mr. Shen led the design and construction of the first battery manufacturing base in China with a capacity above 10 GWh and the design of the first LFP-battery for xEVs.
At Morlus, Mr. Shen has built a world class team that sets the company in the very forefront of lithium battery technology development. The agreement between Morlus and Elinor covers product development, production, and factory construction.
Investment Decision in 2025
Elinor Batteries aims to launch products for order as early as this fall. Together, Elinor Batteries and Morlus have set a goal of achieving a market-leading position in Europe.
The agreement will accelerate the plans for building the gigafactory for battery production in Orkland, with an investment decision targeted for 2025.
Exceptional timing
Renewable energy investor Lars Helge Helvig owns the investment company Valinor, the majority owner of Elinor. Helvig believes that the timing is exceptional for investing in batteries from Norway.
“The battery market is booming, and Europe is striving to become self-sufficient in batteries. According to the IEA, new energy storage is crucial for 60% of the emission reductions needed in the energy sector by 2030. Batteries are now the world’s fastest-growing energy technology,” Helvig explains.
Global footprint
For Morlus, the collaboration with Elinor Batteries represents an opportunity to grow its global footprint.
“Norway is the country with the highest proportion of renewable energy globally, and it has a strong industrial foundation. Both will enable us to produce a green and low-carbon battery, which is unique,” says Shen Xi.
“The Elinor team has demonstrated exceptional professionalism, efficiency, and immense passion for the work they will undertake. Coupled with their investor Valinor’s rich experience in the renewable energy sector, this gives us strong confidence in our future collaboration.”
About Elinor Batteries
Elinor, founded by Valinor, is a Norwegian battery production company offering competitive and sustainable batteries for the BESS market. The company is headquartered in Trondheim and plans to establish a gigafactory in the Eiktyr giga-site and industrial park in Orkland municipality.
About Jiangsu Morlus Technology Company Limited
Morlus has developed a range of industry-leading battery products and built significant capacity in battery research, development, and production. Among its largest shareholders, in addition to founders and employees, are Gongniu Electrics/Bull Electrics, Zhengxuan Investment, and China-Singapore Suzhou Industrial Park Development Group. The company holds more than 70 patents, with factories located in Nantong and its development center in Shenzhen.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828783500/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Debiopharm’s Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistance14.10.2026 14:00:00 CEST | Press release
Despite the remarkable progress made by ADCs, many cancer patients continue to face disease progression due to treatment resistance, tumor heterogeneity, and dose-limiting toxicities At World ADC 2026 San Diego, Debiopharm presented their latest ADC innovation to overcome these challenges with novel linker-payload technology, including modular dual payload linker MLINK DUO and modular cathepsin B-cleavable linker MLINK Select Research results with various MultiLINKTM Linker Technologies showcased broadening of vedotin-based ADC therapeutic index for MLINK Select ADCs, synergistic antitumor activity with MLINK Duo, and homogeneous DAR8 conjugation with MLINK HiSol Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced their latest research on antibody drug conjugate (ADC) research released at World ADC San Diego 2026. Results highlighted the pre-cli
Responsible AI for Children: IEEE Delivers a Trusted Safety Formula to Help Protect Kids Online14.10.2026 14:00:00 CEST | Press release
With children’s AI exposure surging, IEEE Standards Association certification helps ensure AI products for kids are ethically designed, independently tested and continually accountable for safety and well-beingFirst product certification issued to educational platform from Greek National Centre for Scientific Research The IEEE Standards Association, the global, consensus-building standards development organization of IEEE – the world’s largest technical professional organization and public charity dedicated to advancing technology for the benefit of humanity – today advanced its Responsible AI for Children (RAIC) Certification Program with the first product certified for children’s online safety. As children increasingly engage with digital and AI-enabled technologies, parents, educators, developers, and regulators want tools they can trust. IEEE’s Responsible AI for Children (RAIC) certification directly addresses these needs by translating global technical standards into a practical
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 202614.10.2026 14:00:00 CEST | Press release
− TAK-881 met its primary endpoint, demonstrating pharmacokinetic comparability to HYQVIA® in patients 16 years and older − TAK-881 may shorten infusion times and offer the opportunity for fewer required infusion sites compared to HYQVIA with 50% less volume while maintaining up to once-monthly dosing − Adult infection outcomes and safety and tolerability profiles were comparable to HYQVIA based on descriptive analyses and consistent with established IG therapy standards Takeda (TSE:4502/NYSE:TAK) announced detailed results from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) and Recombinant Human Hyaluronidase], which, if approved, has the potential to become the first facilitated SCIG 20% therapy for patients with Primary Immunodeficiency Disease (PID) administered up to once-monthly (every 3 to 4 weeks). Data in participants aged 16 years and older are featured in two late-b
Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Boardof Directors14.10.2026 13:55:00 CEST | Press release
Tirman, through his family office Abri Capital Ltd., holds 26 million DVLT shares and brings over 35 years of international investment management and corporate restructuring experience to the Company Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced the appointment of Jeffrey Tirman to its Board of Directors, effective as of October 12, 2026. Mr. Tirman was designated by NYIAX, Inc. (“NYIAX”) in connection with Datavault AI's recently completed acquisition of NYIAX, and he previously served on NYIAX's board of directors. As a Datavault AI Shareholder, Mr. Tirman brings both an ownership perspective and extensive management experience to the Board. Mr. Tirman has more than 35 years of international investment management experience, focused on corporate transformation, capital strategy and value creation. He has led c
EZO Reaches Financial Close on €150 Million Senior Debt Facility14.10.2026 13:21:00 CEST | Press release
Investment-grade, non-recourse financing will support the delivery of more than 3,000 charge points primarily across the whole of the UK along with additional development in Ireland. EZO has reached financial close on a €150 million investment-grade, non-recourse, senior debt facility. The funding will finance the design, installation, operation and maintenance of over 3,000 charge points, representing over 100,000 kWs of capacity, across the UK and Ireland under mostly long-term public sector “PPP-like” concessions with an attractive risk allocation between the public and private sector that will significantly advance EV infrastructure delivery, on time and to budget. These charge points are estimated to generate well in excess of £1 billion in electricity sales over the next 20 years, a portion of which will be shared with the public sector while, at the end of the concession, the chargers will revert back to the public sector. Headquartered in Ireland, EZO has expanded rapidly into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom